indazoles has been researched along with erlotinib hydrochloride in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.00) | 29.6817 |
| 2010's | 18 (90.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mancuso, A; Sternberg, CN | 1 |
| Greten, TF; Manns, MP; Plentz, RR | 1 |
| Khurana, V; Minocha, M; Mitra, AK; Pal, D; Qin, B | 1 |
| Adjei, AA; Burris, HA; Dy, GK; Eckhardt, SG; Huff, A; Infante, JR; Jones, SF; Ma, WW; Novello, S; Ottesen, LH; Suttle, AB; Wang, Q | 1 |
| Amler, LC; Brachmann, RK; Fridlyand, J; Friedman, LS; Hampton, GM; Haverty, PM; Huw, L; Koeppen, H; Lackner, MR; Mohan, S; O'Brien, C; Pandita, A; Ross, L; Sampath, D; Shames, DS; Spoerke, JM | 1 |
| Boeck, S; Haas, M; Heinemann, V; Holdenrieder, S; Kern, C; Nagel, D; Stieber, P; Wittwer, C | 1 |
| Klempner, SJ; Mills, GB; Myers, AP; Westin, SN | 1 |
| Behera, R; Mensa-Wilmot, K; Thomas, SM | 1 |
| Adkins, J; Aldrich, J; Asmann, Y; Baker, A; Barr Fritcher, EG; Barrett, MT; Bhavsar, JD; Bible, KC; Block, M; Borad, MJ; Bryce, AH; Carpten, JD; Champion, MD; Cherni, I; Christoforides, A; Collins, JM; Condjella, RM; Craig, DW; Egan, JB; Fonseca, R; Han, H; Harris, P; Hunt, K; Izatt, T; Kipp, BR; Klee, EW; Kocher, JP; Kurdoglu, A; Lazaridis, KN; Liang, WS; Lobello, J; Mastrian, SD; McCullough, AE; McDonald, J; McWilliams, RR; Middha, S; Nair, AA; Nasser, S; Oliver, GR; Patel, MD; Phillips, L; Placek, P; Reiman, R; Schahl, K; Silva, AC; Stewart, AK; Von Hoff, D; Watanabe, AT; Young, SW | 1 |
| Aguilar, H; Balart, J; Barril, X; Beijersbergen, RL; Bonifaci, N; Bostner, J; Brunet, J; Burnstein, KL; Bustelo, XR; Caizzi, L; Carlson, KE; Clarke, R; Climent, F; Di Croce, L; Esteller, M; Extremera, AI; Figueras, A; Fornander, T; García, N; Garcia-Mata, R; Gil, M; Gómez-Baldó, L; Halonen, P; Islam, A; Jansen, MP; Karlsson, E; Katzenellenbogen, JA; Kiyotani, K; Martrat, G; Mushiroda, T; Nakamura, Y; Nevedomskaya, E; Pérez Tenorio, G; Pujana, MA; Rodríguez-Peña, AB; Rodríguez-Vida, A; Serra-Musach, J; Sgroi, DC; Soler, MT; Stål, O; Urruticoechea, A; Villanueva, A; Vizoso, M; Zembutsu, H; Zwart, W | 1 |
| Berndsen, RH; Ding, X; Dyson, PJ; Griffioen, AW; Ho, CM; Nowak-Sliwinska, P; van den Bergh, H; Weiss, A | 1 |
| Baumgardner, M; Bryan, MC; Chen, Y; Eigenbrot, C; Fan, P; Gu, XH; Hanan, EJ; Heffron, TP; La, H; Malek, S; Purkey, HE; Schaefer, G; Schmidt, S; Sideris, S; Yen, I; Yu, C | 1 |
| Albiges, L; Bensalah, K; Bex, A; Canfield, SE; Dabestani, S; Fernández-Pello, S; Giles, RH; Hofmann, F; Hora, M; Kuczyk, MA; Lam, TB; Ljungberg, B; Marconi, L; Merseburger, AS; Powles, T; Staehler, M; Tahbaz, R; Volpe, A | 1 |
| Choe, SW; Kim, MJ; Kim, YH; Lee, YJ; P Oh, S; Sprecher, D | 1 |
| Bowles, DW; Lackner, MR; Leong, S; Moss, RA; Schellens, JHM; Schutzman, JL; Shankar, G; Spoerke, JM; van der Noll, R; Voest, EE; Ware, JA; Zhou, J | 1 |
| Arbour, KC; Riely, GJ | 1 |
| Burris, HA; Daniel, DB; Finney, L; Gian, VG; Greco, FA; Hainsworth, JD; Heymach, JV; Lipman, AJ; Shih, KC; Spigel, DR; Waterhouse, DM | 1 |
| Brown, B; Molloy, MP; Neilson, KA; Semaan, C | 1 |
| Abdel-Aziz, HA; Abdelsalam, EA; Abou Taleb, NA; Amin, KM; Eldehna, WM; Hammad, SF; Mekawey, AAI; Zaghary, WA | 1 |
| Edeline, J; Frenel, JS; Gilabert, M; Raoul, JL; Senellart, H | 1 |
5 review(s) available for indazoles and erlotinib hydrochloride
| Article | Year |
|---|---|
New treatment approaches in metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Erlotinib Hydrochloride; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2006 |
Molecular therapy of pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzenesulfonates; Bevacizumab; Capecitabine; Carcinoma, Pancreatic Ductal; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Neoplasm Invasiveness; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phthalazines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
Topics: Antineoplastic Agents; Benzodioxoles; Carcinoma, Ovarian Epithelial; Erlotinib Hydrochloride; Female; Humans; Indazoles; Indoles; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sulfonamides | 2013 |
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Topics: Anilides; Antineoplastic Agents; Axitinib; Benzimidazoles; Bevacizumab; Carcinoma, Renal Cell; Comparative Effectiveness Research; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Quinolines; Quinolones; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2017 |
[Proton pump inhibitors and cancers: A hazardous association?]
Topics: Antineoplastic Agents; Bacterial Infections; Capecitabine; Contraindications, Drug; Drug Interactions; Dysbiosis; Erlotinib Hydrochloride; Fractures, Bone; Gastrointestinal Absorption; Gastrointestinal Neoplasms; Gefitinib; Humans; Indazoles; Kidney; Neoplasms; Prognosis; Protein-Tyrosine Kinases; Proton Pump Inhibitors; Pyrimidines; Sulfonamides | 2020 |
4 trial(s) available for indazoles and erlotinib hydrochloride
| Article | Year |
|---|---|
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Demography; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Pyrimidines; Quinazolines; Sulfonamides; Treatment Outcome | 2013 |
Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Albumins; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoembryonic Antigen; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Keratin-19; Middle Aged; Multivariate Analysis; Oximes; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Piperazines; Prospective Studies; Quinazolines; Sirolimus; Sulfonamides; Survival Rate | 2013 |
A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Indazoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Sulfonamides | 2017 |
Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Placebos; Progression-Free Survival; Proteomics; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides | 2018 |
11 other study(ies) available for indazoles and erlotinib hydrochloride
| Article | Year |
|---|---|
Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Cell Line; Dogs; Erlotinib Hydrochloride; Indazoles; Male; Mice; Morpholines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Sulfonamides | 2012 |
Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Comparative Genomic Hybridization; DNA Copy Number Variations; DNA Mutational Analysis; Drug Synergism; Erlotinib Hydrochloride; Female; Gene Amplification; Humans; Indazoles; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; PTEN Phosphohydrolase; Pyrimidines; Quinazolines; Signal Transduction; Sulfonamides; Transcriptome; Xenograft Model Antitumor Assays | 2012 |
New chemical scaffolds for human african trypanosomiasis lead discovery from a screen of tyrosine kinase inhibitor drugs.
Topics: Animals; Axitinib; Benzamides; Erlotinib Hydrochloride; Female; HeLa Cells; Humans; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lapatinib; Mice; Morpholines; Piperazines; Protein Kinase Inhibitors; Purines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Trypanosomiasis, African | 2014 |
Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocarcinoma; ErbB Receptors; Erlotinib Hydrochloride; Genome, Human; Humans; Imidazoles; Indazoles; Molecular Targeted Therapy; Mutation; Prognosis; Protein Kinase Inhibitors; Pyridazines; Pyrimidines; Quinazolines; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; Sulfonamides; Transcriptome | 2014 |
VAV3 mediates resistance to breast cancer endocrine therapy.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Enzyme Activators; ErbB Receptors; Erlotinib Hydrochloride; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Genetic Association Studies; Genetic Variation; Humans; Indazoles; Letrozole; MCF-7 Cells; Nitriles; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-vav; Quinazolines; RNA Interference; RNA, Small Interfering; Tamoxifen; Toremifene; Triazoles | 2014 |
A streamlined search technology for identification of synergistic drug combinations.
Topics: Antineoplastic Agents; Axitinib; Benzamides; Cell Line, Tumor; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Drug Combinations; Drug Screening Assays, Antitumor; Drug Synergism; Epithelial Cells; Erlotinib Hydrochloride; Humans; Imidazoles; Indazoles; Kidney; Piperazines; Pyrazoles | 2015 |
4-Aminoindazolyl-dihydrofuro[3,4-d]pyrimidines as non-covalent inhibitors of mutant epidermal growth factor receptor tyrosine kinase.
Topics: Acrylamides; Aniline Compounds; Animals; Binding Sites; Crystallography, X-Ray; Dogs; ErbB Receptors; Erlotinib Hydrochloride; Furans; Hepatocytes; High-Throughput Screening Assays; Humans; Hydrogen Bonding; Indazoles; Mice; Microsomes, Liver; Point Mutation; Protein Kinase Inhibitors; Pyrimidines; Rats | 2016 |
Selective effects of oral antiangiogenic tyrosine kinase inhibitors on an animal model of hereditary hemorrhagic telangiectasia.
Topics: Activin Receptors, Type I; Activin Receptors, Type II; Administration, Oral; Administration, Topical; Anemia; Angiogenesis Inhibitors; Animals; Arteriovenous Malformations; Disease Models, Animal; Erlotinib Hydrochloride; Gastrointestinal Hemorrhage; Hemoglobins; Image Processing, Computer-Assisted; Indazoles; Mice; Mice, Knockout; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Skin; Sorafenib; Sulfonamides; Sulfones; Telangiectasia, Hereditary Hemorrhagic; Tyrosine; Vascular Endothelial Growth Factor A; Wound Healing | 2017 |
Improving therapy for patients with epidermal growth factor receptor-mutant lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Indazoles; Lung Neoplasms; Proteomics; Pyrimidines; Sulfonamides | 2018 |
Pharmacological Inhibition of Casein Kinase 2 Enhances the Effectiveness of PI3K Inhibition in Colon Cancer Cells.
Topics: Casein Kinase II; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neoplasms; Drug Synergism; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Imidazoles; Indazoles; MAP Kinase Signaling System; Mutation; Naphthyridines; Oximes; Phenazines; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins B-raf; Sulfonamides | 2018 |
Synthesis and in vitro anticancer evaluation of some fused indazoles, quinazolines and quinolines as potential EGFR inhibitors.
Topics: Antineoplastic Agents; Binding Sites; Catalytic Domain; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Indazoles; Molecular Docking Simulation; Protein Kinase Inhibitors; Quinazolines; Quinolines; Structure-Activity Relationship | 2019 |